{
  "success": true,
  "pagesUsed": [
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - DR Severity",
        "text": "To demonstrate that brolucizumab is superior to PRP in reducing diabetic retinopathy (DR) severity after 54 weeks of treatment by assessing the proportion of subjects with no PDR at Week 54",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - DME Prevention",
        "text": "To demonstrate that brolucizumab is superior to PRP in preventing the development of center-involved diabetic macular edema (DME) up to Week 54 by assessing the proportion of subjects with center-involved DME up to Week 54",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Visual Acuity AUC",
        "text": "To compare the effect of brolucizumab relative to PRP with respect to visual acuity by assessing the area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - DR Status",
        "text": "To compare the effect of brolucizumab relative to PRP on DR status by assessing the change from Baseline in ETDRS diabetic retinopathy severity scale (DRSS) score at Week 54 and Week 96 and the proportion of subjects with no PDR at Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective - Ocular Complications",
        "text": "To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications associated with DR up to Week 54 and Week 96 and the proportion of subjects with center-involved DME up to Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Safety Objective",
        "text": "To assess the safety and tolerability of brolucizumab relative to PRP",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change from Baseline in BCVA at Week 54",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - No PDR at Week 54",
        "text": "Proportion of subjects with no PDR at Week 54",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - DME up to Week 54",
        "text": "Proportion of subjects with center-involved DME up to Week 54",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint - BCVA AUC",
        "text": "Area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint - DRSS Score",
        "text": "Change from Baseline in ETDRS Diabetic Retinopathy Severity Scale (DRSS) score at Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint - No PDR at Week 96",
        "text": "Proportion of subjects with no PDR at Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint - Vision-threatening Complications",
        "text": "Proportion of study eyes developing vision-threatening complications associated with diabetic retinopathy up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint - DME up to Week 96",
        "text": "Proportion of subjects with center-involved DME up to Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Safety Endpoint",
        "text": "Incidence of ocular and non-ocular adverse events (AE) up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Alternative DR/DME treatment",
            "text": "Application of alternative diabetic retinopathy or diabetic macular edema treatments to the study eye",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Permanent discontinuation of study treatment prior to Week 54",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg (3 x q6w loading then q12w maintenance) vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters",
        "variableOfInterest": "Change from Baseline in BCVA at Week 54",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "First Key Secondary Estimand",
        "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters Summary measure: Odds ratio or risk difference.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death of the subject prior to Week 54",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters",
        "variableOfInterest": "Proportion of subjects with no PDR (DRSS score < 61) at Week 54",
        "summaryMeasure": "Odds ratio or risk difference"
      },
      {
        "id": "est_3",
        "name": "DME Prevention Estimand",
        "populationSummary": "Adult patients with PDR and no center-involved DME at baseline Summary measure: Odds ratio or risk difference.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation due to AE",
            "text": "Discontinuation of treatment due to adverse events (e.g., retinal vasculitis)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with PDR and no center-involved DME at baseline",
        "variableOfInterest": "Proportion of subjects with center-involved DME up to Week 54",
        "summaryMeasure": "Odds ratio or risk difference"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 6,
      "exploratoryObjectives": 0,
      "totalEndpoints": 9,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual acuity at Week 54 by assessing the change from Baseline in best corrected visual acuity (BCVA) at Week 54",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Efficacy Objective - DR Severity",
        "text": "To demonstrate that brolucizumab is superior to PRP in reducing diabetic retinopathy (DR) severity after 54 weeks of treatment by assessing the proportion of subjects with no PDR at Week 54",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective - DME Prevention",
        "text": "To demonstrate that brolucizumab is superior to PRP in preventing the development of center-involved diabetic macular edema (DME) up to Week 54 by assessing the proportion of subjects with center-involved DME up to Week 54",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Efficacy Objective - Visual Acuity AUC",
        "text": "To compare the effect of brolucizumab relative to PRP with respect to visual acuity by assessing the area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Efficacy Objective - DR Status",
        "text": "To compare the effect of brolucizumab relative to PRP on DR status by assessing the change from Baseline in ETDRS diabetic retinopathy severity scale (DRSS) score at Week 54 and Week 96 and the proportion of subjects with no PDR at Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Efficacy Objective - Ocular Complications",
        "text": "To compare the effect of brolucizumab relative to PRP on ocular complications by assessing the proportion of subjects developing vision-threatening complications associated with DR up to Week 54 and Week 96 and the proportion of subjects with center-involved DME up to Week 96",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7",
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Safety Objective",
        "text": "To assess the safety and tolerability of brolucizumab relative to PRP",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "Change from Baseline in BCVA at Week 54",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Secondary Efficacy Endpoint - No PDR at Week 54",
        "text": "Proportion of subjects with no PDR at Week 54",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary Efficacy Endpoint - DME up to Week 54",
        "text": "Proportion of subjects with center-involved DME up to Week 54",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary Efficacy Endpoint - BCVA AUC",
        "text": "Area under the curve in change from Baseline in BCVA up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Secondary Efficacy Endpoint - DRSS Score",
        "text": "Change from Baseline in ETDRS Diabetic Retinopathy Severity Scale (DRSS) score at Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Secondary Efficacy Endpoint - No PDR at Week 96",
        "text": "Proportion of subjects with no PDR at Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Secondary Efficacy Endpoint - Vision-threatening Complications",
        "text": "Proportion of study eyes developing vision-threatening complications associated with diabetic retinopathy up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Secondary Efficacy Endpoint - DME up to Week 96",
        "text": "Proportion of subjects with center-involved DME up to Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "Secondary Safety Endpoint",
        "text": "Incidence of ocular and non-ocular adverse events (AE) up to Week 54 and Week 96",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters Summary measure: Difference in least squares means.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Alternative DR/DME treatment",
            "text": "Application of alternative diabetic retinopathy or diabetic macular edema treatments to the study eye",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Permanent discontinuation of study treatment prior to Week 54",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg (3 x q6w loading then q12w maintenance) vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters",
        "variableOfInterest": "Change from Baseline in BCVA at Week 54",
        "summaryMeasure": "Difference in least squares means"
      },
      {
        "id": "est_2",
        "name": "First Key Secondary Estimand",
        "populationSummary": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters Summary measure: Odds ratio or risk difference.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Death",
            "text": "Death of the subject prior to Week 54",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with proliferative diabetic retinopathy (PDR) and BCVA ≥ 34 ETDRS letters",
        "variableOfInterest": "Proportion of subjects with no PDR (DRSS score < 61) at Week 54",
        "summaryMeasure": "Odds ratio or risk difference"
      },
      {
        "id": "est_3",
        "name": "DME Prevention Estimand",
        "populationSummary": "Adult patients with PDR and no center-involved DME at baseline Summary measure: Odds ratio or risk difference.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation due to AE",
            "text": "Discontinuation of treatment due to adverse events (e.g., retinal vasculitis)",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Brolucizumab 6 mg vs Panretinal photocoagulation (PRP)",
        "analysisPopulation": "Adult patients with PDR and no center-involved DME at baseline",
        "variableOfInterest": "Proportion of subjects with center-involved DME up to Week 54",
        "summaryMeasure": "Odds ratio or risk difference"
      }
    ]
  }
}